This HTML5 document contains 36 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n13http://linked.opendata.cz/resource/drugbank/drug/DB03578/identifier/pdb/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/drug/DB03578/identifier/pubchem-compound/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB03578/identifier/pubchem-substance/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB03578/identifier/drugbank/

Statements

Subject Item
n2:DB03578
rdf:type
n3:Drug
n3:group
experimental
owl:sameAs
n6:DB03578 n8:DB03578
dcterms:title
Pyruvamide
adms:identifier
n10:79088 n11:46506818 n12:DB03578 n13:PYM
n3:synthesisReference
Madhup K. Dhaon, John A. Houbion, "Method of synthesizing the precursor pyruvamide." U.S. Patent US5312985, issued February, 1992.
n3:IUPAC-Name
n4:271B5574-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B557A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5579-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5576-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5577-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5578-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5572-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5570-363D-11E5-9242-09173F13E4C5 n4:271B5573-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5571-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5580-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5581-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B557B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B557C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B557E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B557D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B557F-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5586-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5588-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5589-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5585-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5584-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5587-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5575-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5582-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5583-363D-11E5-9242-09173F13E4C5